-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Biogen, Lowers Price Target to $220

Benzinga·05/02/2025 15:38:59
Listen to the news
Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $265 to $220.